August’s jobs number came in at three times expectations, and the September rate hike odds jumped accordingly. Lululemon cut its full-year outlook for the second time after declining Americas sales. 

Today’s edition covers the jobs shock, what it means for the Fed, and everything that moved.

Elon's mysterious Texas project will be 3X the size of Central Park…

Cost $122 billion to build… And singlehandedly DOUBLE American chip production.

One investment (not Tesla/SpaceX) is at the center of it all.

Click here to get its name and free ticker.

*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

You’re looking at one company making the biggest acquisition in its history and another marketplace finally showing signs of renewed growth. Elite Trade Club Insider readers are seeing what happened underneath those stories: one director voluntarily put $6.55 million into the stock immediately after a massive strategic bet, while three insiders at another company sold roughly $3 million through transactions that were largely decided months ago.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

August added 162,000 jobs against a 53,000 consensus; July's reported loss was revised to a gain, and September rate-hike odds jumped from 52% to 60%; Trump promptly posted on Truth Social, demanding cuts anyway.

Lululemon cut its full-year guidance for the second time this year after declining Americas revenue — the brand that defined aspirational athleisure is now losing to a consumer who won't pay $128 for leggings.

Guidewire Software beat Q4 but guided Q1 below estimates; diesel hit an all-time record of $5.85 a gallon, adding a fresh inflation headline to an already complicated Fed setup.

Volkswagen approved a plan to cut 100,000 jobs and halve its model lineup, while FHFA chief Pulte renewed his push against legacy credit scores by letting Fannie and Freddie accept VantageScore mortgages. All eyes now turn to the August CPI on September 11 — the last data point before the Fed meets on the 16th.

Blackstone’s flagship private-credit vehicle received roughly $4.3 billion in redemption requests during the third quarter, about 10% of outstanding shares, as investors continued seeking liquidity from the $77.2 billion BCRED fund after elevated requests in the previous quarter.

BCRED will repurchase shares equal to its 5% quarterly net-asset-value limit, and nearly $750 million of new subscriptions partly offset withdrawals, and analysts estimate a large portion of the latest requests were resubmitted by investors who were not fully redeemed earlier.  

Blue Owl Technology Finance completed a $150 million private note placement carrying a 7.60% interest rate and maturing in 2032, bringing the specialty lender’s total debt capital raised since June 30 to $800 million as it finances a portfolio concentrated in U.S. technology companies.

The company ended the second quarter with more than $2 billion of cash and available capacity and held investments worth $14.7 billion across 205 portfolio companies, giving it additional financing flexibility as it continues deploying capital into software and other technology-related businesses.

Ionis Pharmaceuticals won FDA approval for Zanvastro, making the therapy the first disease-modifying treatment cleared in the U.S. for Alexander disease, an ultra-rare neurological disorder that damages the brain’s white matter and previously had no approved treatment addressing its underlying cause.

Zanvastro is administered by spinal injection every three months and works by reducing production of the GFAP protein responsible for the disease, giving Ionis another commercial opportunity from its RNA-targeted medicines portfolio.

Intellia Therapeutics secured a $400 million debt facility from OrbiMed, receiving $75 million upfront with another $325 million tied to milestones as the CRISPR developer strengthens its finances ahead of several clinical and regulatory events.

The financing gives Intellia additional runway as it works toward a planned U.S. approval and commercial launch of lonvoguran ziclumeran, its one-time gene-editing treatment for hereditary angioedema, without immediately raising equity capital.

NANO Nuclear Energy signed a new fuel-cycle collaboration agreement with Enveniam to explore nuclear fuel transportation, domestic supply, advanced manufacturing, microreactor commercialization, and energy projects aimed at data centers and remote communities.

The companies will establish a joint working group to identify projects that can move toward funded development, giving NANO Nuclear another route to build infrastructure around its KRONOS microreactor platform and broader U.S. nuclear-fuel operations.

Baker Hughes secured a new offshore services contract from BP covering well stimulation across BP’s UK North Sea operations, including both new developments and mature fields where the energy giant is trying to lift recovery and extend productive asset life.

Baker Hughes will deploy its vessel-based StimFORCE system with support from a UK operating base and local supply chain, expanding its role in offshore intervention and production optimization across one of BP’s core European regions.

Every market cycle produces a handful of companies that dramatically outperform the rest.

Our latest screening has identified the 5 Stocks Set to Double — companies showing rare early-stage momentum traits.

These picks carry the same indicators that historically precede strong rallies.

Past reports highlighted stocks that surged +175%, +498%, and +673%.

Get the Free 5 Stocks Set to Double Report.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

SoundHound AI completed its acquisition of LivePerson and appointed John Collins as CFO, adding relationships with 25 Fortune 100 companies and more than 750 patents as it combines LivePerson’s messaging infrastructure with SoundHound’s OASYS platform across voice, web, mobile, SMS and social channels.

The combined company says it now has a debt-free balance sheet after retiring LivePerson’s outstanding debt and is targeting more than $500 million in future revenue from the existing customer base, widening SoundHound’s push into enterprise AI customer engagement.

DocuSign will open its MCP Server globally on September 30, allowing Claude, ChatGPT, Gemini, Copilot, Slack, and other MCP clients to access agreement intelligence and execute governed contract actions through its Iris AI engine without forcing users to move between separate applications.

The rollout extends DocuSign beyond electronic signatures by letting enterprise AI agents analyze contracts, track terms, and carry out agreement workflows with account-level administrative controls, multilingual support, and integrations spanning platforms including Salesforce, Slack, and Oracle.

Tesla began Cybercab rides as regulators opened a review into whether roughly 1,000 of the steering-wheel-free vehicles were properly certified under U.S. safety standards, putting the company’s newest autonomous platform under scrutiny almost immediately after commercial deployment. 

NHTSA is examining how Tesla determined the two-seat robotaxis comply with rules written around conventional controls, creating an early regulatory test for vehicles designed without permanently attached steering wheels, brake pedals, accelerator pedals, or mirrors. 

Pilgrim’s Pride launched a €500 million senior notes offering through its European financing arm, giving the poultry producer fresh capital for general corporate purposes, including funding its planned acquisition of Walkers Deli & Sausage Company and related transaction expenses. 

The offering is not conditional on the Walkers deal closing, giving Pilgrim’s additional financing flexibility as it expands further into prepared foods while maintaining protein-processing and food-production operations across the United States, Mexico and Europe. 

American Outdoor Brands [AOUT] $14.48 (+44.66%)

American Outdoor Brands makes hunting, shooting, and outdoor accessories — knife handles, holsters, safes, and optics for the outdoor lifestyle market. Q1 FY2027 swung the company to non-GAAP profitability: EPS of $0.03 against a consensus estimate of a $0.24 loss — an earnings surprise of 112.5% — with revenue up 25% year-over-year to $37.25 million.

The company raised full-year guidance and the stock responded with one of the cleanest earnings-driven moves of the week.

Greenpro Capital [GRNQ] $18.70 (+24.92%)

Greenpro Capital provides cloud accounting and business advisory services to SMEs in Southeast Asia.

The company has been building institutional positioning around its regional fintech expansion, and today’s 30% gain on 12x average volume reflects active buying rather than thin-float mechanics in a name that is actually generating revenue from a growing client base in a high-growth region.

Mannatech [MTEX] $9.00 (+23.46%)

Mannatech makes glyconutrient-based nutritional supplements sold through a direct sales network. The company swung to profitability on improving direct sales dynamics and reported results that exceeded expectations, sending the stock up 23% on healthy volume.

Mannatech’s global network of independent associates has been recovering, and today’s results confirm the trend is building.

CBL International [BANL] $9.01 (-40.72%)

CBL International distributes marine bunker fuel to ships at ports across Southeast Asia — it has been a recurring summer winner as disruptions in the Strait of Hormuz drove cargo rerouting through Asian ports.

The reversal today is as sharp as the prior gains were: something specific moved against the position, whether earnings data, a large institutional exit, or a shift in the regional shipping demand picture that CBL’s business had been benefiting from.

Inflection Point Acquisition [IPEX] $7.75 (-29.03%)

Inflection Point Acquisition Corp. is a SPAC that has been trading above its trust floor on deal enthusiasm.

Friday’s 29% decline reflects the familiar pattern: September rate hike expectations rising, bond yields elevated, and SPAC deal premiums compressing as investors recalculate the opportunity cost of holding a trust-backed security when risk-free alternatives are paying nearly 5%. Strong Buy rated.

Founder Group [FGL] $9.30 (-28.74%)

Founder Group is an industrial services company that has been declining steadily through the week — down 18% Thursday, down 28% today.

The two-day decline from $13.05 to $9.30 reflects sustained exit pressure from a name with very limited institutional coverage and minimal trading liquidity, where sellers have been unable to exit without moving the price materially in each session.

When the U.S. left the gold standard in 1971, the rules of money changed almost overnight.

Today, with inflation concerns, heavy central-bank gold buying, and questions around the dollar, some investors are taking another look at physical gold for retirement diversification.

This free guide explains the history, the risks, and how eligible retirement funds may be used for gold without triggering an immediate taxable distribution.

See How Retirement Investors Are Adding Physical Gold Before the Next Big Shift

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.